Found: 7
Select item for more details and to access through your institution.
The Contribution of the Minimal Promoter Element to the Activity of Synthetic Promoters Mediating CAR Expression in the Tumor Microenvironment.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 13, p. 7431, doi. 10.3390/ijms23137431
- By:
- Publication type:
- Article
TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 2, p. 339, doi. 10.3390/cancers12020339
- By:
- Publication type:
- Article
Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
- Published in:
- Molecular Oncology, 2023, v. 17, n. 12, p. 2618, doi. 10.1002/1878-0261.13500
- By:
- Publication type:
- Article
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.
- Published in:
- International Journal of Cancer, 2019, v. 145, n. 3, p. 748, doi. 10.1002/ijc.32170
- By:
- Publication type:
- Article
Ubiquitin Accumulation on Disease Associated Protein Aggregates Is Correlated with Nuclear Ubiquitin Depletion, Histone De-Ubiquitination and Impaired DNA Damage Response.
- Published in:
- PLoS ONE, 2017, v. 12, n. 1, p. 1, doi. 10.1371/journal.pone.0169054
- By:
- Publication type:
- Article
Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.838911
- By:
- Publication type:
- Article
Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-39076-8
- By:
- Publication type:
- Article